Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tinlarebant in adolescents with Stargardt disease
CTR20222689Phase 3Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tinlarebant in Fundus Flavimaculatus (FF), sponsored by BrightGene Bio-Medical Technology. Started Dec 2022; status: completed.
02
Drugs
tinlarebant
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on CTR20222689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222689.